文献支持Edelinontrine (PF-04447943) 是一种有效的人重组 PDE9A 抑制剂,IC50 为 12 nM,比作用于其他PDE家族成员选择性高 78 倍 (IC50>1000 nM)。
价格: ¥300
产品详情
文献和实验
相关推荐
保存条件 :4℃
保质期 :详见说明
英文名 :Edelinontrine
库存 :充足
供应商 :杭州昊鑫生物
CAS号 :1082744-20-4
规格 :1mg
Edelinontrine (Synonyms: PF-04447943).
Edelinontrine (PF-04447943) 是一种有效的人重组 PDE9A 抑制剂,IC50 为 12 nM,比作用于其他PDE家族成员选择性高 78 倍 (IC50>1000 nM)。生物活性
Edelinontrine (PF-04447943) is a potent inhibitor of human recombinant PDE9A (IC50=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC50>1000 nM).
IC50 & Target
PDE9
体外研究(In Vitro)
Using recombinant human, rhesus, and rat PDE9A2 in a cell free assay Edelinontrine is shown to have a Ki of 2.8±0.26, 4.5±0.13, and 18.1±1.9 nM (n=4, 11 and 9 respectively). Edelinontrine is found to be highly selective over other PDE enzymes (PDE1, Ki=8600±2121 nM, n = 5; PDE2A3, Ki>99,000 nM; PDE3A, Ki>50,000 nM; PDE4A, Ki>29,000 nM; PDE5A, Ki=14,980±5025 nM, n=5; PDE6C, Ki=5324±2612 nM, n=4; PDE7A2, Ki>75,000 nM; PDE8A, Ki>50,000 nM; PDE10, Ki>51,250±20,056 nM, n=4; PDE11, Ki>80,000 nM) and no other significant activity at ~60 other receptors/enzymes. In HEK whole cells expressing rhesus PDE9A2, Edelinontrine inhibits ANP (0.3 μM) stimulated cGMP with an IC50 of 375±36.9 nM (n=16)[2].
体内研究(In Vivo)
Based on i.v. and p.o. dosing, pharmacokinetic studies with Edelinontrine in the rat indicates a Tmax of 0.3 h, T1/2 of 4.9 h, Cl of 21.7 mL/min/kg and an oral bioavailability of 47%. Thirty minutes following oral administration in rats (1-30 mg/kg), Edelinontrine concentrations dose-dependently increase in blood, brain and cerebrospinal fluid (CSF). The brain:plasma exposure ratios 30 min after dosing range from 0.13 at the 1 mg/kg dose to 0.33 at the 30 mg/kg dose. CSF levels are approximately 50% of brain levels. In mice, Edelinontrine (3, 10, 30 mg/kg p.o.) dose-dependently increases plasma and brain concentrations of Edelinontrine while the brain to plasma ratio ranged from 0.26 to 0.7 although this is not entirely dose dependent. CSF cGMP levels increase in a dose-dependent manner from a basal level of 3 pmol/mL to 13.3 pmol/mL (3.5-fold) at the 30 mg/kg dose. CSF cGMP levels also increase in a dose-dependent manner from a basal level of 3 pmol/mL in vehicle treated animals to 13.3 pmol/mL (3.5-fold) at the 30 mg/kg dose. CSF cGMP levels are elevated at all doses tested with a maximal effect of 3.5 fold increase above controls at 30 mg/kg[2].
分子量
395.46
性状
Solid
Formula
C20H25N7O2
CAS 号
1082744-20-4
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
In Vitro:
DMSO : ≥ 54.6 mg/mL (138.07 mM)
* "≥" means soluble, but saturation unknown.
配制储备液
浓度溶剂体积质量 1 mg 5 mg 10 mg
1 mM 2.5287 mL 12.6435 mL 25.2870 mL
5 mM 0.5057 mL 2.5287 mL 5.0574 mL
10 mM 0.2529 mL 1.2644 mL 2.5287 mL
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80℃, 2 years; -20℃, 1 year。-80℃ 储存时,请在 2 年内使用, -20℃ 储存时,请在 1 年 内使用。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
1.
请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
2.
请依序添加每种溶剂: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
3.
请依序添加每种溶剂: 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
杭州昊鑫生物科技股份有限公司
代理商实名认证
钻石会员
入驻年限:9年